Volume 23, Issue 5 (December & January - Special Issue on COVID-19 2020)                   J Arak Uni Med Sci 2020, 23(5): 666-685 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Agharezaee N, Forouzesh F. SARS-COV-2: History, Genetics, and Treatment. J Arak Uni Med Sci 2020; 23 (5) :666-685
URL: http://jams.arakmu.ac.ir/article-1-6343-en.html
1- Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
2- Department of Genetics, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. , f8forouzesh@gmail.com
Abstract:   (11250 Views)
Background and Aim: Coronaviruses are a large family of viruses that cause disease in humans and animals. Coronavirus Disease 2019 (COVID-19) is an acute respiratory infectious disease caused by a new coronavirus. The World Health Organization has declared this infectious disease as a global pandemic.
Objective: This study aims to review the latest research advances in genetics, pathogenicity, and clinical features of COVID-19, as well as current therapies to combat this disease.
Methods & Materials: This is a systematic review study on articles published from 2010 to 2020 by searching in reputable databases such as PubMed, Scopus, Google Scholar, Web of Science, and ScienceDirect.
Ethical Considerations: Ethical principles have been observed in accordance with the guidelines of the National Ethics Committee and the COPE regulations.
Results: Examining the genome and genetic studies of the virus, it can be said that there are many similarities between different coronavirus types, but there are differences in their genomic and phenotypic structures that can affect their pathogenesis. Re-use of existing therapeutic drugs, previously designed for other infections and viral pathologies is currently the only practical approach to fight COVID-19. The tests for SARS-CoV-2 genome-specific vaccines and the therapeutic antibodies are currently being tested, but they require a long-term process and complete safety testing.
Conclusion: Rapid diagnosis of SARS-CoV-2 infection is the basis of disease control. There is currently no specific antiviral drug approved for SARS-CoV-2 infection. Therefore, preventive measures are necessary to stop and control the spread of COVID-19, according to genetic studies and the obtaining knowledge of the molecular mechanism of this virus.
Full-Text [PDF 8400 kb]   (4005 Downloads) |   |   Full-Text (HTML)  (12487 Views)  
Type of Study: Review Article | Subject: COVID-19
Received: 2020/05/30 | Accepted: 2020/07/28

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2023 CC BY-NC 4.0 | Journal of Arak University of Medical Sciences

Designed & Developed by : Yektaweb